ABVC BioPharma, Inc. (NASDAQ: ABVC) announced today that it has received a US$70,000 licensing payment from its partner ForSeeCon Eye Corporation under their global licensing agreement for Vitargus, the world's first biodegradable vitreous substitute. This latest payment brings the cumulative total received from ForSeeCon to US$566,000. The agreement carries a potential total value of up to US$93.5 million, including up to US$30 million in equity consideration, US$3.5 million in cash licensing payments, and up to US$60 million in future royalties.
Since the start of fiscal 2025, ABVC has received a total of US$1,345,950 in licensing revenues across all current partnerships. These revenues come with minimal incremental costs, as development expenses were largely incurred in prior years. This structure has enabled ABVC to capture high-margin revenues, directly enhancing its financial position while supporting strategic reinvestments. Management expects this trend to continue.
ABVC will allocate this new licensing income to its Good Manufacturing Practice (GMP) pharmaceutical facility in Hsinchu, Taiwan, with the specific goal of preparing for the GMP-compliant production of Vitargus. This facility represents a critical milestone in moving Vitargus from development into scalable, regulatory-compliant manufacturing, which is necessary for future commercialization. Independent market research estimates the global vitreous substitute market at US$2.5 billion in 2024, projected to grow to US$4.1 billion by 2033, as detailed in a Verified Market Reports study.
Dr. Uttam Patil, ABVC's Chief Executive Officer, stated: "We are pleased to receive this additional US$70,000 licensing payment from ForSeeCon, bringing their cumulative payments under the agreement to more than half a million dollars. In 2025 alone, ABVC has already secured US$1.35 million in licensing revenues across multiple partnerships. These high-margin revenues enable us to reinvest directly into our GMP pharmaceutical facility in Hsinchu, where we are laying the groundwork for Vitargus GMP-compliant production. This is a critical step toward moving Vitargus to commercialization and helping to deliver long-term value for our shareholders."
ABVC's licensing framework with multiple partners, including AiBtl, ForSeeCon, and OncoX, and the potential to receive more than US$12 million in future receivables, positions the company to capture both near-term liquidity and long-term growth opportunities in CNS, oncology, and ophthalmology. The company intends to conduct pivotal clinical trials (Phase III) for Vitargus through global partnerships.
